After striking radiopharmaceutical supply deals with pharma giants Novartis and AstraZeneca within the last six months, Niowave is taking steps to meet growing demand for the alpha-emitting is | Niowave has broken ground on a $75 million facility at its campus in Lansing, Michigan, which will produce Actinium-225. The radioisotope supplier expects the facility to become operational in 2028 and to employ 70 people.

After striking radiopharmaceutical supply deals with pharma giants Novartis and AstraZeneca within the last six months, Niowave is taking steps to meet growing demand for…

50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs